ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Free Cash Flow history
Currency unavailable · from the cash flow
No Free Cash Flow data reported for this period type.
Free Cash Flow vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $183.34M USD | +1.1% | +13.2% | 255.4% | |
| LTM Mar 2026 | $158.74M USD | +42.5% | +4.1% | 3935.1% | |
| LTM Mar 2026 | $147.7M USD | -313.4% | — | 460.4% | |
| LTM Mar 2026 | $65.67M USD | — | +2.7% | 7126.6% | |
| LTM Mar 2026 | $58.89M USD | -34.5% | — | 129.9% | |
| LTM Mar 2026 | €48.99M EUR | +29.0% | -9.3% | 364.5% | |
| FY2025 | $42.57M USD | — | — | 228.7% | |
| LTM Mar 2026 | $20.59M USD | +10.2% | +14.1% | — | |
| LTM Mar 2026 | $2.34M USD | -97.9% | -24.8% | 2.9% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +1.1% | +3.4% | 309.9% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.